The effects of medical castration on testes in patients with advanced prostate cancer

Yi-Sheng Huang, Yi Chia Lin, Michael Chin Cheng Lee, Guang Dar Juang, Chung Hsin Yeh, Yi Hong Cheng, Kuang Yu Chou, Hong En Chen, Te Fu Tsai

Research output: Contribution to journalArticle

Abstract

Objective: Because of patients' fear of surgery, the psychological symbolism of the male character, and significant encouragement by urologists, the majority of patients with advanced prostate cancer prefer medical castration as a choice of hormonal treatment. We investigated how the preserved testes were affected by medical castration with luteinizing hormone-releasing hormone (LH-RH) agonist and/or antiandrogen therapy. Materials and Methods: Thirty-four consecutive patients with advanced prostate cancer who underwent a bilateral epididymal-sparing orchiectomy were enrolled in this study. Before surgery, 19 of them had received LH-RH agonists and/or antian-drogens, while the other 15 patients had not. Morphological measurements were made immediately after the operation, and a histological examination was performed by a uropathologist with confirmation by urologists. The axial length, weight, and histopathological findings of the testes and prostate-specific antigen (PSA)/tes-tosterone level were compared between the two groups. Histological changes and characteristics were recorded and analyzed. Results: The median axial length and weight of the testes in the 19 patients with prior medical castration were 2.6 (2.0-3.6) cm and 8.0 (6.0-11.5) g, which significantly differed from those with primary surgical castration [4.0 (2.9-5.0) cm and 12.0 (9.0-17.0) g, both p<0.001]. Moreover, profound atrophic and fibrosclerotic changes were noted in the seminiferous tubules in the group with prior medical castration. Specific findings, including basement membrane thickening and interstitial cell hyperplasia, were noted in specimens with prior medical castration. However, the postoperative serum PSA and testosterone levels did not significantly differ between the two groups. Conclusion: Medical castration in patients with advanced prostate cancer indeed caused a significant reduction in the volume and profound pathological change in the testes, which may compromise a patient's expectation of his self-image (symbol of sexual virility).

Original languageEnglish
Pages (from-to)169-174
Number of pages6
JournalUrological Science
Volume21
Issue number4
DOIs
Publication statusPublished - Dec 2010
Externally publishedYes

Fingerprint

Castration
Testis
Prostatic Neoplasms
Prostate-Specific Antigen
Gonadotropin-Releasing Hormone
Weights and Measures
Androgen Antagonists
Seminiferous Tubules
Orchiectomy
Basement Membrane
Fear
Hyperplasia
Testosterone
Psychology
Therapeutics
Serum

Keywords

  • Castration
  • Neoplasm
  • Prostate cancer
  • Testis

ASJC Scopus subject areas

  • Urology

Cite this

Huang, Y-S., Lin, Y. C., Lee, M. C. C., Juang, G. D., Yeh, C. H., Cheng, Y. H., ... Tsai, T. F. (2010). The effects of medical castration on testes in patients with advanced prostate cancer. Urological Science, 21(4), 169-174. https://doi.org/10.1016/S1879-5226(10)60038-3

The effects of medical castration on testes in patients with advanced prostate cancer. / Huang, Yi-Sheng; Lin, Yi Chia; Lee, Michael Chin Cheng; Juang, Guang Dar; Yeh, Chung Hsin; Cheng, Yi Hong; Chou, Kuang Yu; Chen, Hong En; Tsai, Te Fu.

In: Urological Science, Vol. 21, No. 4, 12.2010, p. 169-174.

Research output: Contribution to journalArticle

Huang, Y-S, Lin, YC, Lee, MCC, Juang, GD, Yeh, CH, Cheng, YH, Chou, KY, Chen, HE & Tsai, TF 2010, 'The effects of medical castration on testes in patients with advanced prostate cancer', Urological Science, vol. 21, no. 4, pp. 169-174. https://doi.org/10.1016/S1879-5226(10)60038-3
Huang, Yi-Sheng ; Lin, Yi Chia ; Lee, Michael Chin Cheng ; Juang, Guang Dar ; Yeh, Chung Hsin ; Cheng, Yi Hong ; Chou, Kuang Yu ; Chen, Hong En ; Tsai, Te Fu. / The effects of medical castration on testes in patients with advanced prostate cancer. In: Urological Science. 2010 ; Vol. 21, No. 4. pp. 169-174.
@article{aec940c480ae43a09fee332e9fb1bba5,
title = "The effects of medical castration on testes in patients with advanced prostate cancer",
abstract = "Objective: Because of patients' fear of surgery, the psychological symbolism of the male character, and significant encouragement by urologists, the majority of patients with advanced prostate cancer prefer medical castration as a choice of hormonal treatment. We investigated how the preserved testes were affected by medical castration with luteinizing hormone-releasing hormone (LH-RH) agonist and/or antiandrogen therapy. Materials and Methods: Thirty-four consecutive patients with advanced prostate cancer who underwent a bilateral epididymal-sparing orchiectomy were enrolled in this study. Before surgery, 19 of them had received LH-RH agonists and/or antian-drogens, while the other 15 patients had not. Morphological measurements were made immediately after the operation, and a histological examination was performed by a uropathologist with confirmation by urologists. The axial length, weight, and histopathological findings of the testes and prostate-specific antigen (PSA)/tes-tosterone level were compared between the two groups. Histological changes and characteristics were recorded and analyzed. Results: The median axial length and weight of the testes in the 19 patients with prior medical castration were 2.6 (2.0-3.6) cm and 8.0 (6.0-11.5) g, which significantly differed from those with primary surgical castration [4.0 (2.9-5.0) cm and 12.0 (9.0-17.0) g, both p<0.001]. Moreover, profound atrophic and fibrosclerotic changes were noted in the seminiferous tubules in the group with prior medical castration. Specific findings, including basement membrane thickening and interstitial cell hyperplasia, were noted in specimens with prior medical castration. However, the postoperative serum PSA and testosterone levels did not significantly differ between the two groups. Conclusion: Medical castration in patients with advanced prostate cancer indeed caused a significant reduction in the volume and profound pathological change in the testes, which may compromise a patient's expectation of his self-image (symbol of sexual virility).",
keywords = "Castration, Neoplasm, Prostate cancer, Testis",
author = "Yi-Sheng Huang and Lin, {Yi Chia} and Lee, {Michael Chin Cheng} and Juang, {Guang Dar} and Yeh, {Chung Hsin} and Cheng, {Yi Hong} and Chou, {Kuang Yu} and Chen, {Hong En} and Tsai, {Te Fu}",
year = "2010",
month = "12",
doi = "10.1016/S1879-5226(10)60038-3",
language = "English",
volume = "21",
pages = "169--174",
journal = "Urological Science",
issn = "1879-5226",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - The effects of medical castration on testes in patients with advanced prostate cancer

AU - Huang, Yi-Sheng

AU - Lin, Yi Chia

AU - Lee, Michael Chin Cheng

AU - Juang, Guang Dar

AU - Yeh, Chung Hsin

AU - Cheng, Yi Hong

AU - Chou, Kuang Yu

AU - Chen, Hong En

AU - Tsai, Te Fu

PY - 2010/12

Y1 - 2010/12

N2 - Objective: Because of patients' fear of surgery, the psychological symbolism of the male character, and significant encouragement by urologists, the majority of patients with advanced prostate cancer prefer medical castration as a choice of hormonal treatment. We investigated how the preserved testes were affected by medical castration with luteinizing hormone-releasing hormone (LH-RH) agonist and/or antiandrogen therapy. Materials and Methods: Thirty-four consecutive patients with advanced prostate cancer who underwent a bilateral epididymal-sparing orchiectomy were enrolled in this study. Before surgery, 19 of them had received LH-RH agonists and/or antian-drogens, while the other 15 patients had not. Morphological measurements were made immediately after the operation, and a histological examination was performed by a uropathologist with confirmation by urologists. The axial length, weight, and histopathological findings of the testes and prostate-specific antigen (PSA)/tes-tosterone level were compared between the two groups. Histological changes and characteristics were recorded and analyzed. Results: The median axial length and weight of the testes in the 19 patients with prior medical castration were 2.6 (2.0-3.6) cm and 8.0 (6.0-11.5) g, which significantly differed from those with primary surgical castration [4.0 (2.9-5.0) cm and 12.0 (9.0-17.0) g, both p<0.001]. Moreover, profound atrophic and fibrosclerotic changes were noted in the seminiferous tubules in the group with prior medical castration. Specific findings, including basement membrane thickening and interstitial cell hyperplasia, were noted in specimens with prior medical castration. However, the postoperative serum PSA and testosterone levels did not significantly differ between the two groups. Conclusion: Medical castration in patients with advanced prostate cancer indeed caused a significant reduction in the volume and profound pathological change in the testes, which may compromise a patient's expectation of his self-image (symbol of sexual virility).

AB - Objective: Because of patients' fear of surgery, the psychological symbolism of the male character, and significant encouragement by urologists, the majority of patients with advanced prostate cancer prefer medical castration as a choice of hormonal treatment. We investigated how the preserved testes were affected by medical castration with luteinizing hormone-releasing hormone (LH-RH) agonist and/or antiandrogen therapy. Materials and Methods: Thirty-four consecutive patients with advanced prostate cancer who underwent a bilateral epididymal-sparing orchiectomy were enrolled in this study. Before surgery, 19 of them had received LH-RH agonists and/or antian-drogens, while the other 15 patients had not. Morphological measurements were made immediately after the operation, and a histological examination was performed by a uropathologist with confirmation by urologists. The axial length, weight, and histopathological findings of the testes and prostate-specific antigen (PSA)/tes-tosterone level were compared between the two groups. Histological changes and characteristics were recorded and analyzed. Results: The median axial length and weight of the testes in the 19 patients with prior medical castration were 2.6 (2.0-3.6) cm and 8.0 (6.0-11.5) g, which significantly differed from those with primary surgical castration [4.0 (2.9-5.0) cm and 12.0 (9.0-17.0) g, both p<0.001]. Moreover, profound atrophic and fibrosclerotic changes were noted in the seminiferous tubules in the group with prior medical castration. Specific findings, including basement membrane thickening and interstitial cell hyperplasia, were noted in specimens with prior medical castration. However, the postoperative serum PSA and testosterone levels did not significantly differ between the two groups. Conclusion: Medical castration in patients with advanced prostate cancer indeed caused a significant reduction in the volume and profound pathological change in the testes, which may compromise a patient's expectation of his self-image (symbol of sexual virility).

KW - Castration

KW - Neoplasm

KW - Prostate cancer

KW - Testis

UR - http://www.scopus.com/inward/record.url?scp=78650137530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650137530&partnerID=8YFLogxK

U2 - 10.1016/S1879-5226(10)60038-3

DO - 10.1016/S1879-5226(10)60038-3

M3 - Article

AN - SCOPUS:78650137530

VL - 21

SP - 169

EP - 174

JO - Urological Science

JF - Urological Science

SN - 1879-5226

IS - 4

ER -